Cullen M H, Harper P G, Woodroffe C M, Kirkbride P, Clarke J
Department of Radiotherapy, Queen Elizabeth Hospital, Birmingham, London.
Br J Urol. 1988 Nov;62(5):454-60. doi: 10.1111/j.1464-410x.1988.tb04396.x.
We have evaluated the 7-drug, alternating, high-dose cisplatin regime for germ cell tumours, designated POMB/ACE, in 55 patients with advanced malignant teratomas and 5 patients with bulky metastatic seminomas. All of the latter and 5 of the teratoma patients had relapsed following radiotherapy, chemotherapy or both. The previously untreated teratoma patients included 13 whose tumours were extragonadal. The primary testicular tumour patients comprised 16 with large and 21 with very large volume metastases according to the Medical Research Council criteria. POMB/ACE is effective therapy for poor risk patients with germ cell tumours (including those with the most advanced disease, i.e. hepatic and cerebral metastases) and prolonged treatment after marker normality seems unnecessary. It is a complex regime with significant toxicity and cannot be recommended for the treatment of patients with germ cell tumours who have an excellent prognosis with simpler, shorter and less toxic treatment.
我们对55例晚期恶性畸胎瘤患者和5例有大块转移灶的精原细胞瘤患者，评估了用于生殖细胞肿瘤的含7种药物的交替大剂量顺铂方案，即POMB/ACE方案。所有后一组患者以及5例畸胎瘤患者在放疗、化疗或放化疗联合治疗后均出现复发。先前未经治疗的畸胎瘤患者中有13例肿瘤位于性腺外。根据医学研究委员会的标准，原发性睾丸肿瘤患者中，16例有大量转移灶，21例有极大量转移灶。POMB/ACE方案对预后不良的生殖细胞肿瘤患者（包括那些患有最晚期疾病，即肝转移和脑转移的患者）是有效的治疗方法，且在标志物恢复正常后延长治疗似乎没有必要。这是一个毒性显著的复杂方案，对于那些采用更简单、更短且毒性更小的治疗方法预后良好的生殖细胞肿瘤患者，不推荐使用该方案进行治疗。
